INSY Insys Therapeutics, Inc.

14.21
+0.79  (6%)
Previous Close 13.42
Open 13.70
Price To book 3.61
Market Cap 1.02B
Shares 72,125,000
Volume 951,758
Short Ratio 13.08
Av. Daily Volume 713,316

SEC filingsSee all SEC filings

  1. 8-K - Current report 17847390
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17825856
  3. 8-K - Current report 17824791
  4. 8-K - Current report 17823045
  5. DEF 14A - Other definitive proxy statements 17765754

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved January 5, 2012.
SUBSYS
Cancer pain
Phase 2 initiated August 2016
Pharmaceutical Cannabidiol (CBD)
Cocaine dependence
Announced approval July 5, 2016.
Dronabinol Oral Solution
AIDS-related anorexia
Phase 2 enrollment initiated February 2016
Pharmaceutical Cannabidiol (CBD)
Infantile spasms (IS)
Phase 3 planned.
Cannabidiol
Epilepsy
Phase 3 data met primary endpoints - August 2016
Buprenorphine
Moderate to severe postoperative pain after bunionectomy
Dose ranging trial to be initiated 1H 2015, with Phase 3 to be initiated 2H 2015. Data due 2016.
Subsys
Acute post-operative pain

Latest News

  1. Insys Therapeutics, Inc. Announces FDA Final Product Label for Syndros
  2. 661 Million Reasons to Like These 3 Marijuana Stocks
  3. Cannabis' Impact on the Brain in This New Study Should Encourage Marijuana Stock Investors
  4. Marijuana Stock Winners of the Week
  5. 3 Top Marijuana Stocks That Are Profitable (but There's a Catch)
  6. Insys Therapeutics Announces Chief Financial Officer Transition
  7. Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit has been Filed against Insys Therapeutics, Inc. (INSY) and Encourages Investors to Contact the Firm
  8. The Klein Law Firm Reminds Investors of the Filing of a Class Action on Behalf of INSYS Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of May 16, 2017
  9. FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against INSYS Therapeutics, Inc. (INSY) and Lead Plaintiff Deadline - May 16, 2017
  10. Edited Transcript of INSY earnings conference call or presentation 9-May-17 2:00pm GMT
  11. What You Need to Know About Marijuana Stocks
  12. The Wagner Firm Reminds Investors of May 16th Deadline in the Class Action Lawsuit Against Insys Therapeutics, Inc.
  13. UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of INSYS Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 16, 2017 - INSY
  14. INSYS Therapeutics, Inc. – Value Analysis (NASDAQ:INSY) : May 11, 2017
  15. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Insys Therapeutics, Inc. - INSY
  16. May 16 Deadline Alert: Tostrud Law Group, P.C. Reminds Investors of Upcoming Deadline in the Class Action Lawsuit Against Insys Therapeutics, Inc.
  17. 3 Top Biotech Stocks For May
  18. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint in U.S. District Court to Recover Losses Suffered by Investors in INSYS Therapeutics, Inc.
  19. Here's Why Marijuana Stock Insys Therapeutics Briefly Plunged As Much As 11%
  20. INSY Investors: GPM Reminds Investors of the May 16 Deadline in the Class Action Lawsuit Against Insys Therapeutics, Inc.

SEC Filings

  1. 8-K - Current report 17847390
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17825856
  3. 8-K - Current report 17824791
  4. 8-K - Current report 17823045
  5. DEF 14A - Other definitive proxy statements 17765754
  6. 8-K - Current report 17763409
  7. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 17750839
  8. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 17750825
  9. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 17750801
  10. 8-K - Current report 17733807